Medicina, Vol. 60 No. 1, 2024.
Pregledni rad
https://doi.org/10.21860/medflum2024_313686
Therapeutic Approach to Psoriasis - Part One: Topical Drugs
Ivan Lukežić
; Sveučilište u Rijeci, Medicinski fakultet, Rijeka, Hrvatska
Nika Hlača
; Sveučilište u Rijeci, Medicinski fakultet, Katedra za dermatovenerologiju, Rijeka, Hrvatska; Klinički bolnički centar Rijeka, Klinika za dermatovenerologiju, Rijeka, Hrvatska
Marijana Vičić
; Sveučilište u Rijeci, Medicinski fakultet, Katedra za dermatovenerologiju, Rijeka, Hrvatska; Klinički bolnički centar Rijeka, Klinika za dermatovenerologiju, Rijeka, Hrvatska
Sažetak
Psoriasis is an immune-mediated chronic inflammatory skin and joint disease. Psoriasis vulgaris, also known as chronic plaque psoriasis, is the most common type of psoriasis and is characterized by the appearance of erythematous squamous plaques accompanied by itching. Guttate psoriasis, erythrodermic and pustular psoriasis, and psoriasis associated with psoriatic arthritis are less common forms of psoriasis. Clinical scoring systems are used to assess the severity of the disease, which is important for selecting the appropriate therapy. Local therapy is the first line of treatment for mild to moderate psoriasis, while systemic therapy is indicated for more severe forms of the disease and patients who do not respond to local therapy or phototherapy. Combining local and systemic therapy, as well as phototherapy, is an option in some cases. According to the Croatian Dermatovenerological Society's guidelines, the first line of topical treatment for psoriasis is a fixed combination of calcipotriol and betamethasone propionate once daily, with the option of proactive treatment twice a week. A fixed combination of calcipotriol and betamethasone propionate once or twice a week is recommended in maintenance therapy. Topical corticosteroids, followed by topical calcineurin inhibitors, are the treatment of choice for psoriasis of the face and intertriginous regions. Topical psoriasis treatment is essential in the treatment of mild to moderate psoriasis, but it also complements systemic therapy in patients with severe psoriasis.
Ključne riječi
Administration, Topical; Calcineurin Inhibitors; Dermatologic Agents; Psoriasis; Vitamin D
Hrčak ID:
313686
URI
Datum izdavanja:
1.3.2024.
Posjeta: 274 *